REBORD: Ephrin B1 Regulation in Human Right Appendage

Sponsor

University Hospital, Toulouse (Other)

Overall Status

Completed

CT.gov ID

NCT01080781

Collaborator

(none)

Enrollment

Location

33.1

Duration (Months)

0.9

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Background : Ephrin-B1 is part of the large Eph/Ephrin system which is involved in cell-cell comunication. The role of Ephrin-B1 has scarcely been studied in adulthood. Our team has shown that this protein is expressed in normal heart in mice and humans. In mice with deletion of the gene encoding Ephrin-B1, we have shown progressive development of dilated cardiomyopathy characterized by dramatic disorganization of cardiac tissue architecture and decreased heart rate variability.
Purpose: Ephrin-B1 protein was recently identified in human heart but its putative role remains unknown. In knockout mice, deletion of efn gene is associated with abnormalities in cardiac architecture linked to defects in cell-cell tight junctions. From a functional point of view, mice develop a dilated cardiomyopathy and exhibit decreased heart rate variability in the frequency domain. The purpose of this study is to assess if Ephrin-B1 expression is regulated in human heart and if expression level correlates with heart rate variability.
Abstract: Thirty patients suffering from cardiac disease needing surgery will be included and separated in two groups according to pressure levels in right auricle /and or pulmonary artery. Ephrin-B1 expression will be assessed in right appendages at both the transcriptional (quantitative PCR) and protein (Western blot) levels. Furthermore, the putative relationship between Ephrin-B1 expression and heart rate variability (24 hours ECG recordings) will be investigated.

Condition or Disease	Intervention/Treatment	Phase
Cardiac Diseases

Detailed Description

Outcomes
Primary: Expression level of gene encoding Ephrin B1 (quantitative PCR normalized against GAPDH gene expression) on human right appendage biopsies
Secondary: a/ Expression level of Ephrin B1 protein on human right appendage using Western blot and b/ Heart rate variability in both time and spectral domains
Study design: Exploratory, monocentric , prospective and comparative. Two groups of 15 patients each, age and sex matched, with or without elevated pressures in right auricles or pulmonary arteries will be included.
Eligibility criteria:
Inclusion criteria: patients needing cardiac surgery and who had both right catheterism and 24 hours ECG recording before inclusion; stable medications for at least 4 weeks; age > 18 years.
Exclusion criteria: Patient with pace-maker or atrial fibrillation
Number of subjects: 30 patients in two groups of 15 patients each.
Statistical analysis: Qualitative and quantitative variables will be compared using McNemar test and t test respectively. A p value < 0.05 will be considered as significant.

Study Design

Study Type:

Observational

Actual Enrollment :

30 participants

Time Perspective:

Prospective

Official Title:

Ephrin B1 Regulation in Human Right Appendage

Study Start Date :

Mar 1, 2010

Actual Primary Completion Date :

Jul 1, 2012

Actual Study Completion Date :

Dec 1, 2012

Arms and Interventions

Arm	Intervention/Treatment
Group 1 normal pressures in right auricle (<10 mmHg) /and or pulmonary artery (<35 mmHg)
Group 2 high pressures in right auricle (> 10 mmHg) /and or pulmonary artery (>35 mmHg)

Outcome Measures

Primary Outcome Measures

Expression level of gene encoding Ephrin-B1 [1 year]
Expression level of gene encoding Ephrin-B1 (quantitative PCR normalized against GAPDH gene expression) on human right appendage biopsies

Secondary Outcome Measures

Expression level of Ephrin B1 protein [1year]
Expression level of Ephrin B1 protein on human right appendage using Western blot and b/ Heart rate variability in both time and spectral domains

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patients needing cardiac surgery and who had both right cardiac catheterism and 24 hours ECG recording before inclusion
Stable medications for at least 4 weeks